Alpha¹ by KaimenConfidential

Kaimen Rigor review

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.

Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Morris VK, Wu C, Usari T, Laliberte R, Dychter SS, Zhang X, Tabernero J, Kopetz S, BREAKWATER Trial Investigators

DOI: 10.1056/NEJMoa2501912
Record issued: 2026-08-10
Engine: 7.29.0
Exported: 2026-09-22

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/e8b64281-056a-4e95-8b5c-7fa0689b5a09 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ReportingKey resources not met−0.5★
ReportingData & code availability not met−0.5★
ReportingEthical approvals partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Biggest issues

01Key resources not identified
highDisclosurereviewer-assessedFull detail
Investigational products are identified with dose and regimen but manufacturer/source is not explicitly stated. Statistical software is not identified. Both applicable criteria are not adequate, leading to a fail.
02Data and code not shared
highDisclosurereviewer-assessedFull detail
No data availability statement is provided; the trial registry is listed but does not constitute a data access statement. This is a clear omission for a clinical trial.

Findings by category

01ArithmeticNone found 02OverreachNone found 103AuthenticityData authenticity concerns 304DisclosureReporting gaps 05AvailabilityNone found 06Copyedit3 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a methodologically strong phase 3 randomized trial: randomization, blinding of primary endpoints, pre-specified power analysis, detailed methods, and proportional conclusions are all well reported, and the 3 machine-verifiable statistics recomputed consistently. The main weaknesses are reporting gaps rather than scientific flaws: no data availability statement, no manufacturers/sources for investigational products, no statistical software identified, and a vague IRB statement (no named committee/protocol number). Copyedit issues are trivial typographical/punctuation problems.

Both independent reviewers converged on all eight dimension statuses (identical 79/100 scores); the only checklist-level divergences were minor (outlier/missing-data handling in study design; limitations-discussed in reporting transparency), resolved by weighing the cited evidence. The statistics verification covered only 3 tests with a statistic+df or effect+CI; threshold-only p-values and untestable statistics were not verified, so statistics are described only as 'reported tests recomputed consistently', not as fully validated. No retracted or not-found references (22 checked); 1 checked link live; trial registered at ClinicalTrials.gov.

Numerical inconsistencies

None found

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Checked — nothing surfaced.

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Recompute two-sided p-value for PFS hazard ratio from reported 95% CI using the log-ratio method.
“HR 0.53 (95% CI 0.407, 0.677; two-sided P<0.0001)”
Find in source
Taken as given: The 95% CI is two-sided and based on the Wald test for the log hazard ratio.; The HR point estimate is 0.53 and the CI bounds are 0.407 and 0.677.; The CI is for the hazard ratio, so log=1 is used.
Method: pCI function using the log HR and its standard error derived from the CI width, assuming a normal distribution for the log HR.
How we recomputed it: pCI(0.53, 0.407, 0.677, 1)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2
Recompute two-sided p-value for OS hazard ratio from reported 95% CI.
“HR 0.49 (95% CI 0.375, 0.632; two-sided P<0.0001)”
Find in source
Taken as given: The 95% CI is two-sided and based on the Wald test for the log hazard ratio.; The HR point estimate is 0.49 and the CI bounds are 0.375 and 0.632.; The CI is for the hazard ratio, so log=1 is used.
Method: pCI function using the log HR and its standard error derived from the CI width, assuming a normal distribution for the log HR.
How we recomputed it: pCI(0.49, 0.375, 0.632, 1)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2
Recompute two-sided p-value from the reported HR and 95% CI for PFS (EC+mFOLFOX6 vs SOC).
“HR 0.53 (95% CI 0.407, 0.677; two-sided P<0.0001)”
Find in source
Taken as given: The HR is on the ratio scale (log=1).; The CI is a two-sided 95% confidence interval.; The estimate and CI are from a Cox proportional hazards model.
Method: Computed p from the log HR and its standard error derived from the CI using a normal approximation.
How we recomputed it: pCI(0.53, 0.407, 0.677, 1)

Overstated conclusions

None found

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Checked — nothing surfaced.

9 major claims checked against the paper's own evidence: all adequately supported.

supportedReviewer 1
EC+mFOLFOX6 demonstrates significant progression-free survival improvement vs. SOC.
The primary analysis of PFS shows HR 0.53 (95% CI 0.407–0.677; P<0.0001), meeting the dual primary endpoint.
Evidence: Results, Efficacy: 'HR 0.53 (95% CI 0.407, 0.677; two-sided P<0.0001); median progression-free survival 12.8 vs. 7.1 months.'
“BREAKWATER met its other dual primary endpoint, demonstrating significant progression-free survival improvement with EC+mFOLFOX6 vs. SOC: hazard ratio (HR) 0.53 (95% confidence interval [CI] 0.407, 0.677; two-sided P<0.0001); median progression-free survival 12.8 vs. 7.1 months.”
AbstractFind in source
supportedReviewer 1
Interim analysis of overall survival demonstrates significant improvement vs. SOC.
The pre-specified interim OS analysis shows HR 0.49 (95% CI 0.375–0.632; P<0.0001), meeting the superiority threshold.
Evidence: Results, Efficacy: 'HR 0.49 (95% CI 0.375, 0.632; two-sided P<0.0001); median overall survival 30.3 vs. 15.1 months.'
“Interim analysis of overall survival demonstrated significant improvement vs. SOC: HR 0.49 (95% CI 0.375, 0.632; two-sided P<0.0001); median overall survival 30.3 vs. 15.1 months.”
AbstractFind in source
supportedReviewers 1, 2
EC+mFOLFOX6 is the first front-line activation pathway-targeted treatment indicated in BRAF V600E-mutant mCRC.
The paper states that accelerated FDA approval was granted based on ORR, and the PFS and OS data further support this claim.
Evidence: Introduction: 'EC+mFOLFOX6 is the first front-line activation pathway-targeted treatment indicated in BRAF V600E-mutant mCRC.'
“EC+mFOLFOX6 is the first front-line activation pathway-targeted treatment indicated in BRAF V600E-mutant mCRC.”
Introduction ¶2Find in source
supportedReviewer 1
Treatment with EC+mFOLFOX6 results in risk of death half that of SOC.
The OS HR of 0.49 corresponds to a 51% reduction in risk of death, as stated.
Evidence: Discussion: 'Treatment with EC+mFOLFOX6 resulted in risk of death that was half (51% lower) of that in the SOC arm.'
“Treatment with EC+mFOLFOX6 resulted in risk of death that was half (51% lower) of that in the SOC arm.”
DiscussionFind in source
supportedReviewer 1
Median overall survival more than doubled with EC+mFOLFOX6 vs. SOC.
Median OS 30.3 months vs. 15.1 months is a >2-fold increase.
Evidence: Results, Efficacy: median OS 30.3 vs. 15.1 months.
“median overall survival (95% CI) was 30.3 months (21.7, not estimable) and 15.1 months (13.7, 17.7) in the EC+mFOLFOX6 and SOC arms, respectively”
ResultsFind in source
supportedReviewers 1, 2
Safety profile of EC+mFOLFOX6 is consistent with known profiles of each agent.
Adverse events are reported and compared with known safety profiles; no new safety signals are identified.
Evidence: Results, Safety; Discussion: 'The safety profile was consistent with that known for each agent and no substantial increase in chemotherapy dose reduction or discontinuation was needed.'
“The safety profile was consistent with that known for each agent and no substantial increase in chemotherapy dose reduction or discontinuation was needed.”
DiscussionFind in source
supportedReviewer 1
BREAKWATER demonstrates statistically significant improvements in PFS and OS with first-line EC+mFOLFOX6 vs. SOC.
Both primary endpoints and the key secondary endpoint are met with statistical significance.
Evidence: Abstract, Conclusion; Results.
“BREAKWATER demonstrated statistically significant improvements in progression-free and overall survival with first-line EC+mFOLFOX6 vs. SOC in patients with BRAF V600E-mutant mCRC.”
ConclusionFind in source
supportedReviewer 2
EC+mFOLFOX6 significantly improves progression-free survival compared to SOC.
The paper provides HR 0.53 (95% CI 0.407-0.677, P<0.0001) with Kaplan-Meier curves and subgroup analyses, adequately supporting the claim.
Evidence: Primary analysis of PFS by blinded independent central review
“BREAKWATER met its other dual primary endpoint, demonstrating significant progression-free survival improvement with EC+mFOLFOX6 vs. SOC: hazard ratio (HR) 0.53 (95% confidence interval [CI] 0.407, 0.677; two-sided P<0.0001); median progression-free survival 12.8 vs. 7.1 months.”
AbstractFind in source
supportedReviewer 2
EC+mFOLFOX6 significantly improves overall survival compared to SOC.
The paper provides HR 0.49 (95% CI 0.375-0.632, P<0.0001) with survival curves, adequately supporting the claim.
Evidence: Interim analysis of overall survival (key secondary endpoint)
“Interim analysis of overall survival demonstrated significant improvement vs. SOC: HR 0.49 (95% CI 0.375, 0.632; two-sided P<0.0001); median overall survival 30.3 vs. 15.1 months.”
AbstractFind in source

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

ADEQUATESurrogate endpoint
The efficacy claim is based on progression-free survival (PFS) and overall survival (OS), which are hard clinical outcomes (disease progression/death and death, respectively). The primary endpoint is PFS by blinded independent central review, and the key secondary endpoint is OS. These are not surrogate biomarkers but direct clinical measures.
“The dual primary endpoints were objective response rate and progression-free survival by blinded independent central review. The key secondary endpoint was overall survival.”
Find in source
ADEQUATEEffect size
The reported effect sizes are large and clinically meaningful. PFS improved from 7.1 to 12.8 months (HR 0.53, 95% CI 0.407–0.677, P<0.0001), and OS improved from 15.1 to 30.3 months (HR 0.49, 95% CI 0.375–0.632, P<0.0001). These are substantial survival benefits with clear statistical support and are anchored to clinical meaningfulness (nearly halved risk of progression/death and death).
“median progression-free survival 12.8 vs. 7.1 months... HR 0.53 (95% CI 0.407, 0.677; two-sided P<0.0001)... median overall survival 30.3 vs. 15.1 months... HR 0.49 (95% CI 0.375, 0.632; two-sided P<0.0001)”
Find in source

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

1 integrity concern flagged (0 high).

lowother
Table 1 contains a typographical error in the C-reactive protein row for the EC+mFOLFOX6 arm: '6(25' is likely missing a space and a percentage sign (should be '6 (2.5)').
6(25
Table 1reviewer’s wording

Reporting gaps

3 findings · worst high

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Key resources not identifiedAssessed
Ethics/consent reporting incompleteAssessed

Eight Dimensions5 pass · 1 warn · 2 fail

Prior work is cited, including the BEACON trial in previously treated patients and the poor prognosis of BRAF V600E-mutant mCRC. The rationale linking BRAF and EGFR co-targeting to overcome feedback reactivation is logically explained. Limitations of prior work (e.g., chemotherapy alone outcomes) are discussed and addressed by the first-line design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper clearly establishes the scientific premise by citing prior research (BEACON trial, ANCHOR study) and the rationale for dual BRAF/EGFR inhibition with chemotherapy in the first-line setting.

Evidence

paraphrase[Introduction, paragraph 1-2]

“Based on results from BEACON, encorafenib plus cetuximab, an anti-EGFR monoclonal antibody, was established as standard of care (SOC) for previously treated BRAF V600E-mutant mCRC.”

“In CRC, BRAF inhibition can cause rapid pathway feedback reactivation through epidermal growth factor receptor (EGFR), attenuating its activity.”

Introduction ¶1Find in source

“A first-line activation pathway-targeted treatment that can demonstrate improved efficacy in BRAF V600E-mutant mCRC is needed.”

Introduction ¶2Find in source

PASSReviewer 2· 95% conf

The paper establishes a clear scientific premise, citing prior work (BEACON, ANCHOR) and providing a rationale for combining targeted therapy with chemotherapy in BRAF V600E-mutant mCRC.

Evidence

paraphrase[Introduction, paragraph 3]

“Based on results from BEACON, encorafenib plus cetuximab, an anti-EGFR monoclonal antibody, was established as standard of care (SOC) for previously treated BRAF V600E-mutant mCRC.”

“A first-line activation pathway-targeted treatment that can demonstrate improved efficacy in BRAF V600E-mutant mCRC is needed.”

Introduction ¶4Find in source

“In the first-line setting, chemotherapy with or without a biologic agent (e.g., bevacizumab) was the SOC for BRAF V600E-mutant mCRC and was associated with inferior outcomes versus BRAF wild-type mCRC (median progression-free survival of 5.8 vs. 9.2 months; median overall survival of 11.1 vs. 23.7 months).”

Introduction ¶3Find in source

Randomization was implemented via Interactive Response Technology with stratification by ECOG status and region. The primary endpoint (PFS) was assessed by blinded independent central review. A power analysis with 85% power at a one-sided alpha of 0.023 was pre-specified with a sample size of 235 per arm. Inclusion and exclusion criteria are detailed. The open-label design is stated and the key endpoint is blinded.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Study design is rigorous: randomization is described, power analysis is provided, inclusion/exclusion criteria are clear, and endpoint assessment is blinded. Missing explicit outlier handling for missing data, but ITT analysis is defined.

Evidence

paraphrase[Methods, Trial Design, Patients, and Treatment]

“Patients were randomized 1:1:1 to receive EC... Randomization stratification factors were Eastern Cooperative Oncology Group performance status... and region... Randomization was implemented by Interactive Response Technology.”

paraphrase[Methods, Statistical Analysis]

“The primary analysis of progression-free survival was preplanned to occur after ≥230 events... this number of events was required to have at least 85% power to detect an HR of 0.67 using a one-sided stratified log-rank test at a significance level of 0.023.”

paraphrase[Methods, Statistical Analysis]

“The statistical analysis mentions 'all patients randomized' for efficacy but does not discuss handling of missing data or outliers beyond standard censoring for survival analysis.”

PASSReviewer 2· 95% conf

The study design is rigorous: randomization with stratification, blinded independent central review for primary endpoints, pre-specified power analysis, and inclusion/exclusion criteria are clearly described.

Evidence

paraphrase[Methods, Trial Design]

“Randomization stratification factors were Eastern Cooperative Oncology Group performance status (0 vs. 1) and region (US/Canada vs. Europe vs. Rest of World). Randomization was implemented by Interactive Response Technology.”

paraphrase[Methods, Endpoints]

“The dual primary endpoints are objective response rate (in the first 110 patients randomized in the EC+mFOLFOX6 and SOC arms, respectively [objective response rate subset]) and progression-free survival both by blinded independent central review.”

“The primary analysis of progression-free survival was preplanned to occur after ≥230 events for the EC+mFOLFOX6 and SOC arms and ≥12 months after the completion of enrollment of the phase 3 portion of the study; this number of events was required to have at least 85% power to detect an HR of 0.67 using a one-sided stratified log-rank test at a significance level of 0.023.”

Statistical analysisFind in source

Table 1 provides sex, age range, and ECOG performance status for each arm. Weight is not reported. Health status is captured by ECOG. Demographics are extensive, including race, tumor side, stage, primary tumor resection, number of organs involved, liver metastases, and biomarkers. Both sexes are enrolled, so sex justification is not applicable.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthINADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Sex, age, and health status (ECOG) are reported in baseline demographics, but weight is not reported. Demographics including race, tumor side, stage, and biomarker status are comprehensive.

Evidence

paraphrase[Table 1]

“Sex — no. (%) Male: 79 (50.0) [EC], 123 (52.1) [EC+mFOLFOX6], 119 (49.0) [SOC]”

paraphrase[Table 1]

“Age — yr Median: 59.0, 60.0, 62.0; Range: 26.0–84.0, 24.0–81.0, 28.0–84.0”

paraphrase[Table 1]

“Race — no. (%) White: 88 (55.7), 141 (59.7), 144 (59.3); Asian: 64 (40.5), 88 (37.3), 91 (37.4); ...”

PASSReviewer 2· 85% conf

Sex, age, ECOG performance status, and demographics are reported in Table 1, but weight is not reported.

Evidence

paraphrase[Table 1]

“Sex — no. (%) | Male | 79 (50.0) | 123 (52.1) | 119 (49.0) | | Female | 79 (50.0) | 113 (47.9) | 124 (51.0) | | Age — yr | Median | 59.0 | 60.0 | 62.0 | | Range | 26.0–84.0 | 24.0–81.0 | 28.0–84.0”

paraphrase[Table 1]

“Race — no. (%) | White | 88 (55.7) | 141 (59.7) | 144 (59.3) | | Asian | 64 (40.5) | 88 (37.3) | 91 (37.4)”

absence[Table 1]

Weight is not reported.

The paper states that the protocol was approved by 'the relevant ethics committee/institutional review board at each site' but does not name a specific committee or provide a protocol number. Informed consent is described. Regulatory compliance with the Declaration of Helsinki, ICH-GCP, and applicable laws is stated.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementINADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 90% conf

Informed consent and regulatory compliance are adequately reported, but the IRB/ethics committee statement is vague (no named committee or protocol number). This triggers a warning.

Evidence

“The protocol, including amendments, is available at NEJM.org and was approved by the relevant ethics committee/institutional review board at each site.”

MethodsFind in source

“Informed consent was obtained from patients before enrollment.”

MethodsFind in source

paraphrase[Methods, Trial Oversight]

“BREAKWATER was performed in accordance with consensus ethical principles derived from international guidelines, including the Declaration of Helsinki and CIOMS International Ethical Guidelines, applicable International Conference on Harmonization Good Clinical Practice guidelines...”

WARNReviewer 2· 90% conf

The ethics statement is vague ('approved by the relevant ethics committee/institutional review board at each site') without naming the committee or providing a protocol number, which is inadequate. Informed consent was obtained and regulatory compliance is stated.

Evidence

“The protocol, including amendments, is available at NEJM.org and was approved by the relevant ethics committee/institutional review board at each site.”

MethodsFind in source

“Informed consent was obtained from patients before enrollment.”

MethodsFind in source

paraphrase[Methods, Trial Oversight]

The drugs (encorafenib, cetuximab, oxaliplatin, leucovorin, 5-FU, bevacizumab) are named with dose and regimen but manufacturer/source is not provided. The statistical analysis software (e.g., SAS, R) is not mentioned. Other resources (antibodies, cell lines, etc.) are not applicable because this is a clinical trial without wet-lab assays.

Sub-criteria

mycoplasma testingN/A

reagents identifiedINADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

FAILReviewer 1· 85% conf

Investigational products are identified with dose and regimen but manufacturer/source is not explicitly stated. Statistical software is not identified. Both applicable criteria are not adequate, leading to a fail.

Evidence

paraphrase[Methods, Trial Design, Patients, and Treatment]

“EC (encorafenib 300 mg orally once daily; cetuximab 500 mg/m2 intravenously once every 2 weeks), EC+mFOLFOX6 (encorafenib 300 mg orally once daily; cetuximab 500 mg/m2 intravenously once every 2 weeks; oxaliplatin 85 mg/m2 intravenously, leucovorin 400 mg/m2 intravenously, and 5-FU 400 mg/m2 intravenous bolus, then 5-FU 2400 mg/m2 continuous intravenous infusion over 46–48 hours, all once every 2 weeks [mFOLFOX6; 28-day cycle])”

absence[Methods, Statistical Analysis]

Statistical software is not identified.

FAILReviewer 2· 80% conf

The investigational products (encorafenib, cetuximab, chemotherapy) are named with dosing regimens but manufacturers/sources are not identified. No statistical software is identified.

Evidence

paraphrase[Methods, Trial Design, Patients, and Treatment]

absence[Methods, Trial Design, Patients, and Treatment]

No manufacturer or source is provided for any drug.

absence[Methods, Statistical Analysis]

No statistical software is identified.

Tests named include stratified log-rank test, Cox proportional hazards model, and Kaplan-Meier method. Effect sizes (HR, OR) with 95% CIs are reported. Data presentation includes Kaplan-Meier curves, forest plots, and tables with per-group n. Exact p-values are given as '<0.0001' rather than exact numbers, which is common but imprecise. Statistical software is not mentioned. Assumptions are handled by design (Cox model). Mathematical plausibility is not applicable due to large N and continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical tests are named, effect sizes with CIs are reported, and data presentation follows clinical trial standards. Exact p-values are reported as thresholds (P<0.0001) rather than exact figures, which is a minor imprecision. Software is not identified, but this does not affect the pass.

Evidence

paraphrase[Methods, Statistical Analysis]

“The primary analysis of progression-free survival was preplanned to occur after ≥230 events... using a one-sided stratified log-rank test at a significance level of 0.023.”

“HR 0.53 (95% CI 0.407, 0.677; two-sided P<0.0001)”

ResultsFind in source

“two-sided P<0.0001”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical tests are named, effect sizes with CIs are reported, data presentation is adequate, and numbers are plausible. However, exact p-values are not reported (only thresholds) and statistical software is not identified.

Evidence

paraphrase[Methods, Statistical Analysis]

“The treatment effect of progression-free survival was evaluated using a Cox proportional hazards model stratified by baseline stratification factors. The HR and its corresponding 95% confidence interval (CI) were reported. The Kaplan–Meier approach was used to estimate median progression-free survival for each arm.”

“HR 0.53 (95% CI 0.407, 0.677; two-sided P<0.0001)”

ResultsFind in source

absence[Methods, Statistical Analysis]

Statistical software is not identified.

The paper mentions the ClinicalTrials.gov identifier (NCT04607421) and states the protocol is available at NEJM.org, but does not include a statement about where the individual patient data or study datasets can be accessed. No repository deposit or accession numbers are provided. Code sharing is not applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementNOT REPORTED

Per reviewer (2) — the votes behind the verdict

FAILReviewer 1· 95% conf

No data availability statement is provided; the trial registry is listed but does not constitute a data access statement. This is a clear omission for a clinical trial.

Evidence

absence[Entire paper]

Data availability statement is absent.

FAILReviewer 2· 95% conf

No data availability statement is present; no repository deposit, accession numbers, or code sharing are mentioned.

Evidence

absence[Entire manuscript]

No data availability statement is present.

absence[Entire manuscript]

No repository deposit or accession numbers are mentioned.

absence[Entire manuscript]

No code sharing is mentioned.

Methods are detailed with dosing regimens, endpoints, and statistical plans. Trial registration number is provided. All pre-specified primary and secondary endpoints are reported. Limitations (open-label, EC arm closure) are discussed. Conclusions are supported by the data. Funding sources and conflict of interest disclosures are present. No reporting guideline checklist is cited.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Methods are complete, trial is registered, all key outcomes are reported, limitations are discussed, conclusions are proportional, and funding/COI are disclosed. The only missing element is a reference to a reporting guideline (e.g., CONSORT), which is not mentioned.

Evidence

paraphrase[Abstract, Methods, and Funding]

“ClinicalTrials.gov number, NCT04607421”

paraphrase[Discussion]

“EC arm enrollment was closed based on the low likelihood of EC demonstrating superiority versus SOC following the results of the phase 2 ANCHOR study...”

paraphrase[Methods]

“No reference to CONSORT or other reporting checklist is found in the paper.”

PASSReviewer 2· 85% conf

The trial is registered, methods are complete, outcomes are reported, and funding/COI are disclosed. However, no reporting guideline checklist is referenced and limitations are not explicitly discussed.

Evidence

paraphrase[Abstract and Methods]

“ClinicalTrials.gov number, NCT04607421”

absence[Methods]

No reporting guideline checklist is referenced.

absence[Discussion]

No dedicated limitations section is present.

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

ClinicalTrials.gov

NCT04607421

ClinicalTrials.gov

NCT05217446

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 22 references by DOI: 17 verified — 5 no DOI (shown, not verified).

NO DOI
Abstract 3790: Preclinical profile of LGX818: a potent and selective RAF kinase inhibitor
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
515MO Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): updated results from the BREAKWATER safety lead-in (SLI)
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC)
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Welcome to the ICH MedDRA website
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

1 data/code link checked; 1 live.

datahttps://clinicaltrials.gov/ct2/show/NCT04607421LIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Copyediting

3 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 3 minor suggestions below.

3 copyedit issues flagged: mostly typo, punctuation.

MINORtypoTable 1, C-reactive protein row for EC+mFOLFOX6 arm
“6(25”
→ 6 (2.5)
Missing space and percentage sign; likely a formatting error.
MINORpunctuationResults, Safety paragraph
“In the EC+mFOLFOX6 and SOC arms the median duration of treatment (range) was 27.0 weeks (2.0 to 153.6), 49.8 weeks (1.3 to 161.9), and 25.9 weeks (2.0 to 150.0) in the EC, EC+mFOLFOX6, and SOC arms, respectively”
→ Add a comma after 'arms' and rephrase for clarity: 'In the EC, EC+mFOLFOX6, and SOC arms, the median duration of treatment (range) was 27.0 weeks (2.0–153.6), 49.8 weeks (1.3–161.9), and 25.9 weeks (2.0–150.0), respectively.'
The sentence is syntactically confusing.
MINORtypoTable 1, C-reactive protein row, Missing entry for EC+mFOLFOX6 arm
“6(25”
→ 6 (2.5)
The entry appears to be missing a space and percentage sign; likely a formatting error.

Kaimen Rigor Action ItemsFinal pass before journal submission

Post-publication robustness is moderate-to-good: the core design, statistics, and conclusions are sound and the findings are not cast into doubt, but an informed reader should weigh several reporting gaps — the absence of a data-availability statement, unnamed drug manufacturers and statistical software, and the vague IRB statement — which are correctable via an erratum/clarification or trial-record update rather than indicating invalid results. The copyedit issues are trivial and do not affect interpretation.

1.
HIGHdata code
Publish a data availability statement (e.g., via erratum or the article's online note) specifying the mechanism for requesting individual participant data, such as a sponsor-managed data-access committee, YODA, or Vivli.
A published data-driven phase 3 trial with no statement on access to participant-level data is a reproducibility gap that an informed reader will weigh.
2.
HIGHreporting
In the Methods section (Trial Design, Patients, and Treatment), identify the manufacturer/source of encorafenib, cetuximab, and each chemotherapy agent (oxaliplatin, leucovorin, 5-FU).
The key_resources dimension fails because investigational products are named with doses but their sources are not identified, which impairs reproducibility.
3.
HIGHstatistics
State the statistical software and version (e.g., SAS 9.4, R 4.x) used for all analyses in the Statistical Analysis section.
Statistical software is not identified, an omission that limits reproducibility of the analyses.
4.
HIGHethics
In the Trial Oversight section, name the specific ethics committee(s)/IRB(s) that approved the protocol and include the protocol number.
The current IRB statement is too vague to be auditable, which is the basis of the ethical_approvals warn.
5.
MEDIUMstatistics
Report exact p-values (e.g., two-sided P=1.2×10^-6) instead of thresholds like 'P<0.0001' in the Results section.
Threshold-only p-values are a minor imprecision that reduces statistical transparency.
6.
MEDIUMreporting
Reference the CONSORT 2010 statement and indicate that a completed CONSORT checklist and flow diagram are available as supplementary material.
No reporting guideline is referenced, and a CONSORT flow diagram of enrollment/randomization/follow-up is an expected adjunct for a phase 3 trial.
7.
MEDIUMstatistics
Add an explicit statement in the Statistical Analysis section describing how missing data and outliers were handled (e.g., censoring rules, imputation, or confirmation that none was performed).
Missing-data/outlier handling is not explicitly described, which was flagged as a reporting gap in study_design.
8.
MEDIUMcopyedit
Fix the Table 1 C-reactive protein entry for the EC+mFOLFOX6 arm: change '6(25' to '6 (2.5)'.
This is a typographical/formatting error (missing space and percent sign) that could be misread as an impossible value.
9.
LOWcopyedit
Rephrase the Results (Safety) sentence on median duration of treatment to 'In the EC, EC+mFOLFOX6, and SOC arms, the median duration of treatment (range) was 27.0 weeks (2.0–153.6), 49.8 weeks (1.3–161.9), and 25.9 weeks (2.0–150.0), respectively.'
The current sentence is syntactically confusing and warrants a punctuation/clarity fix.
10.
LOWreporting
Include body weight or BMI in the baseline demographics table.
Weight is a standard baseline variable in oncology trials and is currently absent from Table 1.
11.
LOWstatistics
Add a brief note on verification of the proportional-hazards assumption for the Cox model (e.g., inspection of Schoenfeld residuals).
This would strengthen the statistical assumptions_verified reporting for the primary PFS analysis.

Full text (32,559 chars)Analyzed: Aug 10, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.

DOI

10.1056/NEJMoa2501912

Record issued

2026-08-10

Engine

7.29.0

Exported

2026-09-22